A carregar...
Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
IMPORTANCE: Immune checkpoint inhibitors have been approved for use as a second-line therapy for hepatocellular carcinoma (HCC) in patients who previously received sorafenib. Pembrolizumab has shown substantial antitumor activity and a favorable toxicity profile as a second-line treatment of HCC. Ho...
Na minha lista:
| Publicado no: | JAMA Netw Open |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7816108/ https://ncbi.nlm.nih.gov/pubmed/33464318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.33761 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|